



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com • Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • CIN : L51496MH2008PLC184997

SPIL/CS/SE/2026-2027/15

Date: 15th May 2026

To,
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828
BSE Trading Symbol: SUDARSHAN
ISIN: INE00TV01023


Sub: Investor Presentation - Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

In terms of Regulation 30 read with Para A of Part A of Schedule III to the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we hereby submit the updated Investor Presentation.

Request you to take the same on your record.

For, **Sudarshan Pharma Industries Limited**


Sachin Mehta
Joint Managing Director



Encl: As above



Sudarshan Pharma Industries Limited

“Innovating Chemistry, Empowering Health”

INVESTOR PRESENTATION

April 2026

E-mail : Compliance@sudarshanpharma.com

Website : www.sudarshanpharma.com

Contact No : CS Nirav shah : 7700966328

COMPANY BACKGROUND & OVERVIEW

A hand wearing a blue nitrile glove is holding a single white, cylindrical tablet between the thumb and index finger. The background is a laboratory setting with several petri dishes containing various colored substances, including brown, orange, and blue. The lighting is bright and even.

A Specialty Chemicals & Pharmaceutical Trading and Manufacturing Company




18 Years

Founded in 2008, Sudarshan Pharma Industries Limited (SPIL) is engaged in manufacturing and sourcing of Chemicals and Pharmaceutical products

Global Reach

The company has marked its presence in India and International markets. Its products have been exported to the UK, Australia, Uzbekistan, Syria, Oman, Taiwan, and MENA regions.




Diversified Products

The Company specializes in host of products from rock chemicals intermediates and API to finish formulations and fully integrated pharmaceutical and chemicals


Esteemed Clients

Key clients in pharmaceutical formulations and specialty chemicals include Intas, Minova, Invision Life sciences, Omkar Pharma, SRF, Astral Pipes, DuPont, Reliance, Bayer Corp, Akzo Nobel etc

Milestones



Milestones






Business Layout

Existing Business Layout

The company is focusing on increasing manufacturing capabilities and has started **Vertical Integration** for expansion in the following segments:



As an organization built on the principles of upward integration within the pharmaceutical industry, we are committed to delivering high-quality products at affordable prices while consistently investing in in-house R&D.



Subsidiaries

SUDARSHAN PHARMA INDUSTRIES LTD.

Wholly Owned Subsidiaries

Ratna Lifescience Private Limited

Existing Products:

- Gemcitabine Hydrochloride
- 2,2-difluoro-2-deoxycytidine-3,5-dibenzoate (T9)
- Imatinib Mesylate
- Capecitabine Intermediate (Cap-5)

Life Science Chemical Private Limited

Existing Products:

- Tannin extracts
- Solvents
- Dyestuffs
- Pigments

51% Ownership

Ishwari Healthcare Private Limited

Existing Products:

- Polyglycolic Acid Sutures
- Polypropylene Mesh
- Infant Feeding Tube
- Thoracic Drainage Catheter



Subsidiaries

SUDARSHAN PHARMA INDUSTRIES LTD.

Wholly Owned Subsidiaries

Sudarshan Pharma Industries Private Limited, Singapore

The Company is engaged in wholesale trading activities across various categories, including basic industrial chemicals.

Sudarshan Pharma Lifescience Private Limited

Existing Products:

- Pharmaceuticals
- Antibiotics, Drugs, Medicines
- Biological Products

Cibachem General Trading LLC, Dubai

Trading activities of all types of goods and ancillary insurance activities

70% Ownership

Sudarshan Maven Pharma Private Limited

Existing Products:

- Pharmaceuticals,
- API & Intermediates,
- Antibiotics, Drugs, Medicines,
- Biological neutraceuticals.

Key Products



SPECIALITY GREEN CHEMICALS

Acetonitrile

Tetrahydrofuran (THF)

1, 4-Dioxane

DMF/DMSO

Meta xylene

N-Heptane

Diethanolamine

NMP (N-Methyl-2-pyrrolidone)

PHARMA DIVISION

Out of 96 products, **56 are registered under the “R” Trade Mark.**

- SPIL has introduced a novel drug delivery system under the *Love Bird “R” Brand*, featuring a **mouth-dissolving strip** with 5 products in this category.
- For the **first time in India**, SPIL has launched specialty products in the cardiac segment, including the **HART KIT LD**, which provides life-saving drugs for first aid in heart attacks.
- The product “**SET DOWN**”, introduced for the first time in India, combines **allopathy and ayurveda** to enable faster recovery from constipation.
- **Top-Selling Brands in the Indian Market** include: *METFOCAL*, *PULMORELIEF AX*, *RD MAC DSR*, *SET DOWN*, *ENAMOL SP Hem D3*, *JIVAN KIT* (Immunity Booster), and *Infort Q-10*, among others.

Key Products



PERFORMANCE CHEMICALS & INTERMEDIATE CAMPAIGN BASIS

- Specialize Performance Chemicals
- Sesamol (3,4-(Methylenedioxy)phenol) CAS. 533-31-3 **(Having Patent Filled on April 16th 2026).**
- 4-((4-Fluorophenyl)imino)methylphenol CAS. 3382-63-6
- (S)-3-[5-(4-Fluorophenyl)-1,5-dioxopentyl]-4-phenyloxazolidin-2-one CAS. 189028-93-1
- (S)-3-((2R,5S)-5-(4-Fluorophenyl)-2-((S)-((4-fluorophenyl)amino)(4-((trimethylsilyl)oxy)phenyl)methyl)-5-((trimethylsilyl)oxy)pentanoyl)-4-phenyloxazolidin-2-one CAS. 272778-12-8
- Meldrums acid CAS. 2033-24-1
- 4-Nitro benzene sulfonyl chloride CAS. 98-74-8
- CIS LACTUM CAS. 189028-93-1
- 2,2-Dimethyl-1,2-dimethyl-4,6-dione CAS.2033-24-1
- 3-Morpholino-2-cyanoacrylamide CAS. 25229-97-4
- 3-Aminopyrazole-4-carboxamide Hemisulphate CAS. 27511-79-1
- 4-(chlorosulfonyl)benzoic acid CAS. 10130-89-9
- Piperidine-2-carbonyl chloride Hydrochloride CAS. 98626-58-5
- N-(2,6-dimethylphenyl) piperidine-2-carxamide hydrochloride CAS. 65797-42-4
- 1-Butyl-N-(2,6-dimethylphenyl) piperidine-2-carboxamide CAS. 27262-48-2
- (S)-piperidine-2-carboxylic acid Hydrochloride CAS. 2133-33-7
- (S)-N-(2,6-Dimethylphenyl)piperidine-2-carboxamide Hydrochloride CAS. 27262-40-4
- (S)-N-(2,6-dimethylphenyl) -1-propylpiperidine-2-carboxamid“ CAS. 84057-95-4
- 2H-1,3-Benzodioxol-5-ol CAS.533-31-3
- 4-Hydrazino Benzoic acid CAS.619-67-0
- 2-Ethoxyethyl 4-methylbenzenesulfonate CAS. 17178-11-9
- 2-Methyl-2-phenylpropionic Acid CAS. 826-55-1
- Tert-butyl 4-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate CAS. 953071-73-3
- 4-(2-Chloroacetyl)-N-methoxy-N,α,α-trimethyl-benzeneacetamide CAS. 1638785-15-5
- 4-(2-Chloroethyl)-N-methoxy-N,α,α-trimethyl-benzeneacetamide CAS. 1638785-17-7

Key Products



PERFORMANCE CHEMICALS & INTERMEDIATE CAMPAIGN BASIS

- 1-(2-Ethoxyethyl)-2-(piperidin-4-yl)-1H-benzo[d]imidazole Hydrochloride Sesquihydrate CAS.1841081-72-8
- 4-Hydrazinobenzoic acid CAS. 24589-77-3
- (S)-1-(2-Chloroacetyl)pyrrolidine-2-carbonitrile CAS. 20757-35-5
- 3 – Amino – 1 – Adamantanol CAS. 702-82-9
- 3-[2-(3-Chlorophenyl)ethyl]-2-pyridinecarbonitrile CAS. 31255-57-9
- 8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one CAS. 31251-41-9
- 2-[4-[4-[4-(Hydroxydiphenylmethyl)-1-piperidinyl]-1-oxobutyl]phenyl]-2,2-dimethylacetic acid methyl ester CAS.154477-55-1
- Methyl 2-(4-(4-chlorobutanoyl)phenyl)-2-methylpropanoate CAS. 154477-54-0
- Methyl 2-(4-(4-chlorobutanoyl)phenyl)-2-methylpropanoate CAS. 154477-54-0
- 2-Deoxy-2,2-difluoro-D-erythro-pentofuranose-3,5-dibenzoate-1-methanesulfonate CAS. 122111-11-9
- 2-Deoxy-2,2-difluoro-D-erythro-pentafuranous-1-ulose-3,5-dibenzoate CAS. 122111-01-7
- 2-Deoxy-2,2-difluoro-D-ribofuranose-3,5-dibenzoate-1-methanesulfonate CAS. 134877-42-2
- 5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide CAS. 106133-20-4
- 5-Acetyl-2-methoxybenzene sulfonamide CAS.116091-63-5
- (1S,2R,3S,5R)-3-(Phenylmethoxy)-2-[(phenylmethoxy)methyl]-6-oxabicyclo[3.1.0]hexane CAS.110567-22-1
- 2-Amino-1,9-dihydro-9-[(1S,3R,4S)-4-(benzyloxy)-3-(benzyloxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one CAS. 142217-81-0
- (1S-trans)-2-[(Phenylmethoxy)methyl]-3-cyclopenten-1-ol CAS. 110567-21-0
- 5R)-3-(4-Bromo-3-fluorophenyl)-5-hydroxymethylloxazolidin-2-one CAS. 444335-16-4
- 5-Bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine CAS 380380-64-3
- 2-(2-Methyl-2H-tetrazol-5-yl)pyridine-5-boronic acid pinacol ester CAS.1056039-83-8

API IN PROCESS R&D

Trimetazidine
Brivaracetam
Oxcarbazepine
Loratadine

Linagliptin
Vigabatrin
Bilastine
Favipiravir

Gliclazide
Lidocaine
Molnupiravir
Oseltamavir

Ezetimibe
Fexofenadine
Apixaban
Flurbiprofen

Allopurinol
Fluconazole
Rivaroxaban
Fexofinidine Hcl

Probenecid
Oxcarbazepine
Deferasirox
Tamsulocine

Bupivacaine
Atorvasatin calcium
Sitagliptin
Enticavir

Ropivacaine
Latanoprost
Tedizolide

Export Opportunity



In FY 25-26: We Targeted Majorly on our Own Manufacturing API Products Including (Oncology) and Finish Formulation (Keeping Products Registration on priority) and Non-Regulated Market for which we have made the Loan Licenses with many Manufacturers to be Cost Effective and Quality Supplies of Products and Achieved Total Export Turnover of Rs.21.85 Cr

In FY 26-27: We want to Strengthen the Segments and Target the Regulated and Semi Regulated Markets. Also increase the API Product Range which will be of High Value which will give the boost in Export for Regulated Market like Europe and USA Market. Our Target For FY 26-27: Min Rs.100 Cr

In FY 27-28: We want to Strengthen the OTC and Regulated Market and Form Depot to Various Countries for Stock and Sale and Increase the Finish Formulation Registration in Regulated Market.

Operating in over 10 countries globally



Exporting Countries




SUDARSHAN PHARMA – SRIGEN NEW MANUFACTURING UNIT



Hyderabad Unit


Hyderabad Unit is bulk drug & intermediate manufacturing unit. It has developed about 50 potential API Key starting materials and also having an outstanding commercial technology. Few key starting materials holds Patent rights and those intermediates were currently in manufacturing commercial scale with proper regulatory documentation support. The said unit has a reactor capacity in its manufacturing facility and more than that, it will be executed at its contract manufacturing GMP facility located at Hyderabad.




Ratna Lifescience : Turnaround story



Revenue from Operations (Rs Cr)



Profit After Tax (Rs Cr)



Prior to take-over, Ratna Life was operating at a loss. Since the takeover by the Company, Ratna Life has turned around into a profitable organization, achieving significant growth in profit after tax (PAT).





Sudarshan Pharma Industries Limited : Palghar plant



- The company has established **Unit 2 in Palghar, Maharashtra**
- The facility's core operations cover a broad spectrum of activities, including raw material testing, formulation dispensing, batch manufacturing in line with approved standards, as well as packaging, storage, and dispatch of finished products
- It houses an oral liquid production section with a 1,000-litre capacity tank, enabling a production output of 2,000 litres per shift, scalable to 6,000 litres across two shifts
- The company has received approvals for 50 products for both domestic and international markets
- The product portfolio includes **Antibiotics, Cough Syrups, Antipyretics, Antifungals, Antiallergics, and Multivitamins**, among others

MANUFACTURING FACILITY HYDERABAD UNIT

Factory Site



R&D Center



Synthetic R&D



2021/11/3 11:11



2021/11/3 15:57



HPLC AR&D

2021/11/3 16:02



QC wet lab

Key Milestone – Global Certifications

The Company achieved a significant milestone by securing key global certifications for its manufacturing facility in Hyderabad, Telangana. The Company has been awarded the Good Manufacturing Practice (GMP) certification for the manufacturing of API intermediates and active pharmaceutical ingredients, along with the ISO 9001:2015 certification for its quality management system. Both certifications reflect the Company's strong commitment to maintaining international quality standards, operational excellence, and continuous improvement. These recognitions not only enhance the Company's credibility and reliability as a compliant manufacturer but also strengthen its positioning in the pharmaceutical and API sector, enabling it to expand into regulated global markets and drive sustainable long-term growth.

Lead Management



Mr. Hemal V. Mehta | Chairman & Managing Director

Hemal Mehta, Founder-Promoter and Chairman & Managing Director of Sudarshan Pharma Industries Ltd., brings 26 years of extensive experience in the pharmaceutical and chemical manufacturing industry. He is recognized for his expertise in innovation and technology, driving the development of advanced and innovative products aimed at addressing incurable diseases



Mr. Sachin V. Mehta | Joint Managing Director

Sachin Mehta, Founder-Promoter, Joint Managing Director of Sudarshan Pharma Industries Ltd., excels in sourcing specialty chemicals, leading R&D initiatives, developing import substitutes and driving business excellence. His strategic leadership plays a pivotal role in the Company's growth and innovation

Board of Directors




Vijay Ojha | Independent Director



Mr. Vijay Ojha is a result oriented Biotech Professional with General Management knowledge having about 29+ years of Industrial experience in R&D, Project and Production. Comprehensive knowledge of Microbiology, Fermentation, Downstream Purification and Analytical. Worked on different Primary and Secondary metabolites.

Jaya Singhania | Independent Director



Registered as an Independent Director with the databank of IICA. She has authored numerous write-ups on corporate & allied laws. She is a staunch believer in creating leaders as the knowledge has to be passed down and can't be retained. Recently, she has been listed as one of the Top Best Ten Women Legal Consultants in India 2021 by Women Entrepreneur Magazine.

Rushabh Patil | Independent Director



Adv. Rushabh Prashant Patil is a Practicing Independent Advocate in the Bombay High Court & District courts with a demonstrated history of working in the legal fraternity. He has acted as an advisory for several clients on corporate and commercial transactions including strategic alliance and routine advisory on civil matters.

Anil Ghoghare | Non-Executive Director



Presently working as Advisor, Director in various Pharmaceutical companies and is the Promoter of M/S. Pharma-In-Future Technology & GMP/Regulatory consultant & having following subsidiaries for design of plant, technology transfers, regulatory support. He has 37+ years of experience. His vision includes Create excellence in Technology, Facility design and GMP work culture through people, technology & teamwork in Pharmaceutical field.

Newly Appointed Chief Financial Officer



Mr. Sharad Kathawate | Chief Financial Officer w.e.f. 1st May, 2026



A dynamic and results-driven CFO with over 25 years of leadership experience across manufacturing and infrastructure sectors, including start-ups, he brings strong academic credentials with qualifications in M.Com, LLB, AICAI, MBA (Finance) and CS (Final). He possesses deep expertise in finance and operations management, covering treasury, working capital, cash flow management, capital budgeting, costing, taxation, and corporate governance. He has a proven track record of driving business growth, enhancing profitability, and implementing robust financial controls, process efficiencies, and change management initiatives. Additionally, he has extensive experience in IPO execution, including end-to-end compliance, financial structuring, and successful listing management, making him a valuable addition to the Company's leadership team.

Newly Appointed Independent Director



Mr. Sanat Bhat | Independent Director w.e.f. 1st May, 2026



Mr. Sanat Bhat is an accomplished finance professional and entrepreneur with over 13 years of experience spanning Transaction Advisory, Investment Banking, and Corporate Governance. A Chartered Accountant (CA) holding an Additional Diploma in International Taxation (ADIT), he has a proven track record in founding sovereign-backed ventures in Southeast Asia, building IBM's M&A practice in the region, and advising on real estate and infrastructure transactions under the mentorship of veteran transaction advisor Mr. Bobby Parikh. His expertise lies at the intersection of strategic financial planning and technological innovation — with particular strength in solving for special situations of companies seeking restructuring, capital optimization, or cross-border expansion. This combination of transactional depth and digital fluency makes him a valuable asset to boards seeking digital transformation oversight, robust risk management, and independent financial stewardship.

Newly Appointed Non-Executive Director



Mr. Vinay Pandey | Non - Executive Director w.e.f. 1st May, 2026



Dr. Vinay Kumar Pandey is a geotechnical expert with 24+ years of experience, having led complex infrastructure projects including metro systems, high-speed rail, and hydropower developments such as Mumbai Metro Line 3 and India's bullet train. He is the Director of GEOSP Engineers & Consultant LLP, known for bridging engineering design with execution and driving strategic, high-stakes project decisions. His expertise spans underground construction, foundation engineering, risk mitigation, and infrastructure in challenging terrains. A distinguished academic contributor, he has authored 35+ research publications and 4 books, and is actively involved with bodies like the Indian Geotechnical Society and BIS. With strong governance, compliance, and risk management capabilities, he brings valuable board-level insight aligned with infrastructure growth and ESG-driven leadership.

Senior Consultants



Dr. Vishwas Joshi

Dr. S Venkat Rao

Dr. Lanka Rao

Mr. Dhruvit Patel

Dr. Rajesh Patil

Dr. Purshotam Madupu



Senior Key Personnel

1. Mr. Raju Sanghvi

Senior Accountant

7. Mrs. Namrata Mehta

Vice President (Sales)

2. Mr. Santosh Thakur

Import Manger

8. Mr. Bhavesh Kanakia

Vice President - Purchase

3. Mr. Shrinivas Patil

Sales Manager

9. Mr. Amit Yadav

Finance Manager

4. Mrs. Shrishti Mayekar

Sales Head

10. Ms. Sidhi Ganve

Banking Manager

5. Mrs. Priti Muni

President (Sales)

11. Ms. Sonam Mishra

Account Manager

6. Mrs. Devangi Mehta

Vice President (Sales)

12. Mr. Amit Mehta

Purchase Manager

Senior Key Personnel



13. Mr. Milan Shah

Purchase Manager

19. Mr. Mayank Vyas

President (Business Development Manager)

14. Mr. Nirav Shah

CS & Compliance Officer

20. Mr. Vishal Bhosale

Production Head (Jejuri)

15. Mr. Vasantrai Mehta

President (Admin)

21. Mr. Kuldeep Devgude

QC (Jejuri)

16. Mr. Jatin Mehta

Vice President (Admin)

22. Mr. Gummalampati Peda

Production head (Hyderabad Unit)

17. Mrs. Darshana Mehta

Vice President (Admin)

23. Mr. Siva Sankarrao Gollu

QA (Hyderabad Unit)

18. Mr. Rahul Pandey

President (Business Operations & Development)

24. Mr. Anjaneya Raju Ponnamanda

QC (Hyderabad Unit)

OUR ESTEEMED CLIENTELE



S SANDOZ



Cipla

Zydus



Viyash



teva





INDIA- a strong exporter of pharma & Specialty Chemicals Globally



A significant and rising player in the Global Pharmaceutical industry

India's drugs and pharmaceutical exports stood at US\$ 27.9 billion in FY24

India is the 12th largest exporter of medical goods in the world



FDI inflows in the Indian drugs and Pharma sector reached US\$236 Mn. between April 2023-June 2024

Indian drugs are exported to more than 200 countries in the world, with the US being the key market

The country's pharmaceutical sector contributes 6.6% to the total merchandise exports

India ranks 3rd by volume & 14th by value in pharmaceutical production

Addressing the Opportunity



The central government has earmarked ~Rs { @ 100 billion for the bulk drug industry, including Rs 30 billion for the promotion of bulk drug 3 parks (for the next five years) and Rs 69.4 billion for a production-linked incentive scheme for the promotion of domestic manufacturing of critical ~ *KSMs/Drug Intermediates and APIs in the country (for next eight years).

The scheme has identified 53 critical APIs/Intermediates where India's reliance on China is high and most of which are used to produce essential drugs

Sudarshan Pharma is setting up a manufacturing unit to manufacture few of the critical APIs imported by China



Key Problem Area



Dependence on China for Import of key APIs

Categories	Imports from China (%)
Antibiotics	75-80
Hormones, Prostaglandins, Thromboxane & Leukotrienes	50-55
Pro-Vitamins & Vitamins	55-60
Other heterocyclic compounds	80-85
Other organic compounds	70-75



India imports ~70% of Intermediate required for APIs (Active Pharmaceutical Ingredients) from China. Imports from China have been increasing over the years



Also, the pandemic which started spreading in the previous year (2020) has resulted in supply disruptions and price rises for key APIs.



Over the last few years, many chemical-based companies have been shut down in China due to failure to meet environment norms. Such step in the bulk drug industry will adversely impact the Indian API industry and subsequently the formulations industry



Further, the Chinese bulk drug industry receives extensive support from the Government in the form of subsidies. Any change in policy on this front will also lead to pressure on margins for the Indian players

Key value Proposition



Why Invest in Sudarshan Pharma Industries Limited

Sudarshan Pharma Industries Limited delivers **trusted pharmaceutical solutions** through a strong focus on **quality, compliance, and long-term partnerships**. With a robust portfolio of Specialty chemicals , Advanced Intermediates , Active Pharmaceutical Ingredient's (API) & excipients and we consistently meet **IP, BP, and USP standards**, ensuring reliability for regulated markets.

Our strength lies in **ethical operations, transparent documentation, and customer protection**, backed by experienced industry professionals and efficient supply chain management. We prioritize **on-time delivery, technical support, and regulatory readiness**, enabling our partners to scale with confidence.

Driven by a clear growth vision, Sudarshan Pharma Industries is committed to **sustainable expansion, market diversification, and value creation**, making us a dependable and future-ready partner for investors and customers alike.



Key value

For an investor, Sudarshan Pharma Industries emerges as a unique and compelling investment opportunity by combining pharmaceutical innovation, market growth potential, and operational excellence.

Market Pain Point & Opportunity We Address



The global pharmaceutical supply chain faces a critical challenge due to **high dependency on China** for Raw material of specialty chemicals, intermediates and excipients. This dependency exposes manufacturers to **price volatility, inconsistent supply, geopolitical risks, tariff uncertainties, and regulatory disruptions**, impacting cost stability and production timelines. Frequent **rate fluctuations, logistics disruptions, and changing trade policies** have created an urgent need for **reliable, compliant, and diversified sourcing alternatives** for regulated markets.

Market Gap:

Over-dependence on China leading to price volatility, supply uncertainty, and tariff risks.



Our Value:

A compliant, reliable, India-based alternative delivering quality, stability, and long-term supply assurance.



Our Solution – The Sudarshan Advantage

Sudarshan Pharma Industries addresses this gap by offering a trusted India-based alternative to China. We deliver high-quality Specialty Chemicals, Advanced Intermediates, APIs, and Excipients manufactured and sourced in compliance with IP, BP, and USP standards, ensuring consistency, transparency, and long-term supply security.



- ✓ Cost stability and predictable pricing
- ✓ Supply chain resilience
- ✓ Tariff and geopolitical risk mitigation
- ✓ Regulatory-ready documentation for global markets

How Our Products & Services Solve the Market Problem



Problem: China dependency → **Solution:** India-based compliant manufacturing

Result: Stable, secure & future-ready pharma supply chain

FOCUSED MARKET




New Export Avenues



New Clintele



Major African Markets





Key Developments in Sudarshan

Sudarshan Pharma Industries Limited | Investor Presentation



R&D for New Molecules & New Technology in association with Amity University

SPIL has entered into a strategic partnership with Dr. William Selvamurthy at Amity University, a distinguished leader in global education who has established a benchmark for excellence by aligning educational practices, theories, resources, and standards with international best practices.

This collaboration has been formally recognized by Amity University, Noida campus, and encompasses the following key areas:

- Joint initiatives in Nanotechnology
- Collaborative efforts in Pharmaceutical and Healthcare Research & Development (R&D)
- Partnership in Patent writing and submission processes
- Commercialization of innovative technologies and R&D products
- Engagement in clinical studies and patent filings



SPIL Team with Dr. William Selvamurthy

About Dr. William Selvamurthy:

Dr. Selvamurthy is a highly respected Indian scientist, currently serving as the President of the Amity Science, Technology, and Innovation Foundation and the Director General of the Amity Directorate of Science and Innovation at Amity University, Raipur. He has previously held the position of Chief Controller for Research & Development (Life Sciences & International Cooperation) at the Defence Research and Development Organisation (DRDO) of the Government of India.

Dr. Selvamurthy's accolades include the Atma-Swasthya Sri (2012), National Award for S&T Innovations (2012) presented by the Prime Minister, and various other prestigious honors such as the Achanta Lakshmipathi Oration (2011), DRDO Technology Leadership Award (2010), among others.

In recognition of the engagement, Sudarshan Pharma was honored with the "Amity Shield" and "Airavata" mementos from Dr. Tinku Basu, Director of Amity University.



Amity Shield



Airavata



New Products & Markets

Some of Our New Products :

Chemical Sector:

- 1, 4-Dioxane
- 2 Methyl THF
- Acetonitrile
- IODINE
- Pyridin
- Meta Xylene

Pharma Sector:

- Fluconazole,
- Levocetirizine Dihydrochloride,
- Chlorzoxazone,
- Pregabalin,
- Mefenamic acid,
- Methylcobalamin

Oncology API's:

- Gemcitabine
- T9
- Apalutamide
- Olaparib
- Crizotinib
- Cisplatin
- Lenalidomide

New Clientele:



New Export Avenues



Nepal



TAIWAN



Bangladesh



Qatar



Saudi



UAE



Srilanka



Jordan



Lebanon



Pakistan



Nigeria



Mali



Uganda



Kenya



Somalia



Ghana

Major African Markets

Quarterly Consolidated Profit & Loss Statement




Particulars (Rs.Crs)	March 2026	December 2025	September 2025	June 2025
Revenue from Operations	220.92	168.01	168.87	145.26
Cost of Material Consumed/Other Direct Costs	20.12	13.21	0.31	5.41
Purchases of Stock-in trade	192.61	148.81	171.18	139.53
Change in Inventories of Finished goods & Work in Progress	-22.68	-14.22	-19.17	-15.73
Gross Profit	30.87	20.21	16.55	16.05
Gross Profit Margin (%)	13.97%	12.03%	9.80%	11.05%
EBITDA	20.19	10.87	9.21	9.04
EBITDA Margin (%)	9.14%	6.47%	5.45%	6.22%
Other Income	4.13	1.52	1.86	1.21
Depreciation	1.09	0.91	0.90	0.88
Finance Cost	7.53	6.28	5.94	3.96
Profit before Tax	15.70	5.20	4.23	5.41
Profit before Tax (%)	7.11%	3.10%	2.50%	3.72%
Tax	4.31	1.05	0.36	1.45
Profit After Tax	10.73	4.36	4.18	4.04
PAT Margin (%)	4.86%	2.60%	2.48%	2.78%
EPS (As per Profit after Tax)	0.48	0.18	0.16	0.16

Financial Metrics: Focus on Margin Optimization and Profit Growth




Revenue from Operations


INR in Crs



Operating EBITDA & EBITDA Margin (%)



PAT & PAT Margin (%)



Historical Consolidated Profit & Loss Statement



PARTICULARS	31.03.2026 (As per INDAS)	31.03.2025 (As per INDAS)	31.03.2024 (As per IGAAP)
INCOME			
Revenue from Operations	703.06	505.05	463.54
Other Income	8.71	2.52	2.61
Total Income (I)	717.77	507.57	466.15
EXPENSES			
Cost of Materials Consumed	39.06	8.93	6.31
Purchase of Stock-in-Trade	652.13	485.18	424.04
Depreciation and Amortization Expenses	3.79	2.22	1.24
Other Expenses	24.93	20.48	14.61
Total Expenses (II)	681.23	483.12	450.92
Exceptional items	-	2.82	-
Profit before extraordinary items and tax	30.54	21.63	15.23
Extraordinary items	-	-	-
Profit before tax	30.54	21.63	15.23
Total Tax Expenses	7.17	5.75	3.77
Profit/(Loss) for the year/period (before adjustment)	23.30	15.88	11.46
Earning per equity share:			
Basic EPS	0.97	0.66	4.76
Diluted EPS	0.97	0.66	4.76



Historical Consolidated Balance Sheet

PARTICULARS	31.03.2026 (As per INDAS)	31.03.2025 (As per INDAS)	31.03.2024 (As per IGAAP)
I. EQUITY AND LIABILITIES			
(1) Shareholder's Funds			
Share Capital	24.07	24.07	24.07
Reserves and Surplus	132.25	103.52	87.64
(2) Non-Current Liabilities			
Long-Term Borrowings	38.37	10.46	10.49
Other Long Term Liabilities	0.94	0.49	0.09
Deferred Tax Liabilities (Net)	-	0.31	0.02
(3) Current Liabilities			
Short-Term Borrowings	255.11	160.27	94.35
Trade Payables	187.72	91.83	56.72
Other Current Liabilities	6.13	2.14	7.03
Short Term Provisions	7.16	5.50	2.74
Total Equity & Liabilities	641.75	402.41	283.13
II. ASSETS			
(1) Non-Current Assets			
Property, Plant and Equipments and Intangible Assets	96.03	29.91	27.38
Non-Current Investments	11.52	28.84	12.34
Long Term Loans and Advances	31.38	4.56	1.83
Other Non-Current Assets	12.54	4.25	
(2) Current Assets			
Current Investments	-	1.50	1.50
Inventories	218.74	140.48	85.74
Trade Receivables	233.34	160.16	122.55
Cash and Cash Equivalents	1.13	0.55	0.14
Short Term Loans & Advances	9.72	4.61	-
Other Current Assets	27.33	27.54	31.64
Total Assets	641.75	402.41	283.13



Thank you
